Key Questions Answered
Q: What did researchers discover about the serotonin 5-HT1A receptor?
A: They mapped how the 5-HT1A receptor activates distinct brain signaling pathways at the molecular level, clarifying how it influences mood, emotion, and cognition.
Q: Why is this important for antidepressants and antipsychotics?
A: A clearer molecular picture of 5-HT1A signaling can guide the design of faster-acting, more targeted treatments with fewer side effects by showing which signaling routes to engage or avoid.
Q: What unexpected factor affects receptor function?
A: A phospholipid in the cell membrane acts like a co-pilot, shaping how the receptor behaves—an unusual and previously unreported role for this class of receptors.
Summary: Researchers at the Icahn School of Medicine at Mount Sinai have produced a detailed molecular map of the serotonin 5-HT1A receptor, a key regulator of mood and a common target of antidepressants and psychedelic-derived therapies. The receptor inherently favors certain signaling pathways—an example of biased signaling—but different drugs can modulate the intensity of those signals. The team also discovered that a membrane phospholipid significantly influences receptor activity, revealing a novel layer of regulation with implications for drug design and psychiatric treatment.
Key Facts
- Biased signaling: 5-HT1A preferentially activates specific intracellular pathways regardless of the ligand.
- Lipid modulation: A membrane phospholipid acts as an allosteric modulator, steering receptor behavior.
- Therapeutic potential: These structural insights support development of more selective antidepressant and antipsychotic drugs with improved efficacy and safety.
Source: Mount Sinai Hospital
Overview
In research published online in Science Advances (August 1), investigators led by Daniel Wacker, PhD, at the Icahn School of Medicine at Mount Sinai used a combination of cellular assays and high-resolution cryo-electron microscopy to dissect how the 5-HT1A serotonin receptor engages different G protein subtypes and how ligands produce distinct signaling outcomes. The 5-HT1A receptor plays a central role in mood regulation and is targeted by many current and experimental psychiatric drugs. Yet until now, its precise molecular behavior and how different drugs bias signaling remained poorly understood.
The team combined receptor pharmacology in engineered cell systems with near-atomic structural snapshots captured by cryo-electron microscopy. These complementary approaches allowed them to compare how different ligands—ranging from classical antidepressants to antipsychotics—alter receptor shape and G protein engagement. The results reveal both orthosteric (binding site) and allosteric (distant site) determinants that govern which G protein subtype the receptor couples to and how strongly each signaling cascade is activated.
One practical implication is pharmacological selectivity: some compounds, including the antipsychotic asenapine, showed selective engagement of a specific signaling route because of relatively weak activity at the receptor, whereas other ligands produced broader activation profiles. Mapping these preferences provides a roadmap for designing compounds that selectively stimulate therapeutic pathways while avoiding those that produce side effects.
The most unexpected discovery was the significant role of a phospholipid molecule embedded in the receptor’s surrounding membrane. Acting much like a hidden co-factor, this lipid alters receptor conformation and signaling bias—an observation not previously reported across the class of over 700 related G protein–coupled receptors. This lipid influence highlights the importance of membrane environment in receptor pharmacology and opens new avenues for modulating receptor function without directly targeting the orthosteric binding pocket.
Beyond immediate drug design implications, these findings may help explain clinical observations such as delayed therapeutic onset with many standard antidepressants. By revealing which signaling events are necessary for rapid versus delayed effects, researchers can pursue faster-acting interventions for depression, anxiety, psychosis, or chronic pain.
“This molecular map shows us which ‘buttons’ different drugs press on the 5-HT1A receptor and how those choices translate into cellular responses,” says Daniel Wacker. “With this level of detail, we can better predict which strategies are likely to yield effective, targeted treatments with fewer side effects.”
Next steps for the team include deeper investigation of the phospholipid cofactor’s role in vivo and translating structure-guided findings into novel drug candidates. The researchers are already building on these structural insights to design compounds that bias 5-HT1A signaling toward therapeutic pathways.
The paper is titled “Structural determinants of G protein subtype selectivity at the serotonin receptor 5-HT1A.” Authors listed on the publication include Audrey L. Warren, Gregory Zilberg, Anwar Abbassi, Alejandro Abraham, Shifan Yang, and Daniel Wacker. Funding was provided in part by NIH grant GM133504, NIH training and fellowship awards, and related grants supporting this structural pharmacology work.
About this neuroscience and neuropharmacology research news
Author: Karin Eskenazi
Source: Mount Sinai Hospital
Contact: Karin Eskenazi – Mount Sinai Hospital
Image credit: Neuroscience News
Original research (open access): Structural determinants of G protein subtype selectivity at the serotonin receptor 5-HT1A. DOI: 10.1126/sciadv.adu9851. Published in Science Advances by Daniel Wacker et al.
Abstract
Structural determinants of G protein subtype selectivity at the serotonin receptor 5-HT1A
Activation of the serotonin receptor 5-HT1A regulates mood and cognition, making it an important target for treating anxiety, depression, and psychosis. Although the receptor signals through inhibitory G proteins, differences in coupling to distinct transducers and the relationship to functional outcomes remain incompletely defined. To elucidate the molecular basis for transducer selectivity and activation, the authors combined structure-activity relationship studies with cryo–electron microscopy to determine structures of 5-HT1A bound to different ligands and G protein subtypes. They identified a potent partial agonist that selectively engages a G protein subtype and used structure-guided mutagenesis and signaling assays to reveal orthosteric and allosteric determinants of agonist-specific transducer stimulation.